We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Vandalia Research Announces Industrial Scale PCR Technology for DNA Production
Product News

Vandalia Research Announces Industrial Scale PCR Technology for DNA Production

Vandalia Research Announces Industrial Scale PCR Technology for DNA Production
Product News

Vandalia Research Announces Industrial Scale PCR Technology for DNA Production


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Vandalia Research Announces Industrial Scale PCR Technology for DNA Production"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Vandalia Research has announced the launch of its Triathlon™ custom DNA amplification service.

The Triathlon™ is a system invented by Vandalia Research to enable the mass production of specific DNA sequences with the polymerase chain reaction.

While PCR has many advantages for DNA manufacturing, there are barriers because of thermal limitations with rapid heating and cooling of aqueous mixtures.

Typically, generating large quantities of DNA using PCR requires that the reaction mixture be distributed into very small tubes for thermal cycling.

The reaction mix is subsequently collected and combined before PCR-amplified DNA products can be used.

The Triathlon™, however, scales a PCR reaction from the bench to an industrial production system.

The Triathlon™'s primary advantage is a continuous method for heating and cooling the PCR reagents, which facilitates processing unlimited volume without having to pool the products from multiple small tubes.

March 28, 2005 marked the expiration of the foundational PCR patents in the U.S.A. and equivalent ex-U.S.A. foundational PCR patents expired on March 28, 2006.

The expiration of these key patents allows PCR to be used for many applications without licensing fees.

Advertisement